

LAG3 Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP6987c**Specification**

**LAG3 Antibody (Center) Blocking Peptide -
Product Information**Primary Accession [P18627](#)**LAG3 Antibody (Center) Blocking Peptide -
Additional Information****Gene ID** 3902**Other Names**Lymphocyte activation gene 3 protein,
LAG-3, Protein FDC, CD223, LAG3, FDC**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP6987c](/products/AP6987c) was selected from the Center region of human LAG3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**LAG3 Antibody (Center) Blocking Peptide -
Protein Information****Name** LAG3 ([HGNC:6476](#))**Synonyms** FDC**LAG3 Antibody (Center) Blocking Peptide -
Background**

Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains.

**LAG3 Antibody (Center) Blocking Peptide -
References**

Smyth,D.J., et.al., BMC Med. Genet. 7, 20 (2006)

Function

Lymphocyte activation gene 3 protein:
Inhibitory receptor on antigen activated
T-cells (PubMed:7805750,
PubMed:8647185,
PubMed:20421648). Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity). FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity). Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed:7805750,
PubMed:8647185,
PubMed:20421648). Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity). Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed:8647185).

Cellular Location

[Lymphocyte activation gene 3 protein]:
Cell membrane; Single-pass type I membrane protein

Tissue Location

Primarily expressed in activated T-cells and a subset of natural killer (NK) cells.

**LAG3 Antibody (Center) Blocking Peptide -
Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)